Lisata Therapeutics, Kuva Labs Collaborate on Cancer Diagnostics

MT Newswires Live

Dec 04, 2024

Lisata Therapeutics (LSTA) and Kuva Labs, a subsidiary of Mi2 Holdings, said Tuesday they entered into a partnership and license agreement under which Kuva will leverage Lisata's iRGD cyclic peptide candidate, certepetide, as a targeting and delivery agent for its NanoMark platform.

Financial details weren't disclosed.

The partnership aims to create advanced magnetic resonance imaging agents for non-invasive detection of solid tumors, the company said, adding that Kuva will cover all development and commercialization costs, while Lisata will provide certepetide.

The agreement includes an upfront license fee, potential milestone payments, and royalties on future sales for Lisata, the companies added.

Price: 2.77, Change: +0.02, Percent Change: +0.65

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/news/2488947702"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2488947702\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2488947702?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2024-12-04 00:16","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2488947702","market":"sg","top_or_hot":-1,"title":"Lisata Therapeutics, Kuva Labs Collaborate on Cancer Diagnostics","media":"MT Newswires Live","content":"<html><body><p> Lisata <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a> (LSTA) and Kuva Labs, a subsidiary of Mi2 Holdings, said Tuesday they entered into a partnership and license agreement under which Kuva will leverage Lisata's iRGD cyclic peptide candidate, certepetide, as a targeting and delivery agent for its NanoMark platform.</p><p>Financial details weren't disclosed.</p><p>The partnership aims to create advanced magnetic resonance imaging agents for non-invasive detection of solid tumors, the company said, adding that Kuva will cover all development and commercialization costs, while Lisata will provide certepetide.</p><p>The agreement includes an upfront license fee, potential milestone payments, and royalties on future sales for Lisata, the companies added.</p><p>Price: 2.77, Change: +0.02, Percent Change: +0.65</p></body></html>","source":"mtnewswires_news","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Lisata Therapeutics, Kuva Labs Collaborate on Cancer Diagnostics</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nLisata Therapeutics, Kuva Labs Collaborate on Cancer Diagnostics\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1092851196\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">MT Newswires Live </p>\n<p class=\"h-time\">2024-12-04 00:16</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html><body><p> Lisata <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a> (LSTA) and Kuva Labs, a subsidiary of Mi2 Holdings, said Tuesday they entered into a partnership and license agreement under which Kuva will leverage Lisata's iRGD cyclic peptide candidate, certepetide, as a targeting and delivery agent for its NanoMark platform.</p><p>Financial details weren't disclosed.</p><p>The partnership aims to create advanced magnetic resonance imaging agents for non-invasive detection of solid tumors, the company said, adding that Kuva will cover all development and commercialization costs, while Lisata will provide certepetide.</p><p>The agreement includes an upfront license fee, potential milestone payments, and royalties on future sales for Lisata, the companies added.</p><p>Price: 2.77, Change: +0.02, Percent Change: +0.65</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4139","symbol_name":"生物科技","start_time":0,"source_url":"https://www.mtnewswires.com/","article_id":"2488947702","we_media_id":"1092851196","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2488947702","pubTimestamp":1733242584,"columns":[],"sourceInfo":{"source_id":"mtnewswires_news","name":"MT Newswires"},"weMediaInfo":{"media_name":"MT Newswires Live","introduction":"The most recognized names in North America, Europe and Asia rely on MT Newswires to power their applications. Better news, better service, better price.","home_visible":1,"id":"1092851196","head_image":"https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e"},"summary":"Lisata Therapeutics  and Kuva Labs, a subsidiary of Mi2 Holdings, said Tuesday they entered into a partnership and license agreement under which Kuva will leverage Lisata's iRGD cyclic peptide candidate, certepetide, as a targeting and delivery agent for its NanoMark platform.Financial details weren't disclosed.The partnership aims to create advanced magnetic resonance imaging agents for non-invasive detection of solid tumors, the company said, adding that Kuva will cover all development and commercialization costs, while Lisata will provide certepetide.The agreement includes an upfront license fee, potential milestone payments, and royalties on future sales for Lisata, the companies added.Price: 2.77, Change: +0.02, Percent Change: +0.65","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4139":"生物科技","LENZ":"Therapeutics","LSTA":"LISATA THERAPEUTICS INC"},"translate_title":"Lisata Therapeutics与Kuva Labs合作开发癌症诊断","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"LSTA":0.9,"LENZ":1},"content_text":"Lisata Therapeutics (LSTA) and Kuva Labs, a subsidiary of Mi2 Holdings, said Tuesday they entered into a partnership and license agreement under which Kuva will leverage Lisata's iRGD cyclic peptide candidate, certepetide, as a targeting and delivery agent for its NanoMark platform.Financial details weren't disclosed.The partnership aims to create advanced magnetic resonance imaging agents for non-invasive detection of solid tumors, the company said, adding that Kuva will cover all development and commercialization costs, while Lisata will provide certepetide.The agreement includes an upfront license fee, potential milestone payments, and royalties on future sales for Lisata, the companies added.Price: 2.77, Change: +0.02, Percent Change: +0.65","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"symbols":[],"gpt_button":1,"need_auth":false,"code":"91000000","status":"200"}}}